Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation between GP resistance and platelet activation index remains poorly understood.
Background
Non-small cell lung cancer (NSCLC) continues to be the cancer with the highest incidence and cancer-related mortality among malignant tumors, accounting for approximately 80% of all diagnosed lung cancer cases. The main reason for poor prognosis is that the great majority of NSCLC patients are diagnosed at an advanced stage [1] . With the development of technology, many methods have been used to treat NSCLC [2] [3] [4] [5] [6] . Chemotherapy has become the standard approach in the treatment of advanced NSCLC [7] . Gemcitabine/cisplatin (GP) serves as first-line doublet chemotherapy for treating advanced NSCLC, with an objective response rate of 20%, median progressionfree-survival of 6.1 months, and median overall survival (OS) time of 13.1 months [8] . Unfortunately, not all the sufferers receive clinical benefits from GP chemotherapy [8] . The majority of patients treated with GP who are GP resistance will eventually become deceased, which suggests that we need to find a suitable marker to predict GP resistance before its use.
Platelets count is commonly used to evaluate whether chemotherapy can be used for patients. Recently, several studies found complex interactions between platelets and tumor cells resulting in tumor progression and metastases [9, 10] . Clinical studies reported that platelet activation index including platelet count (PLC), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) were associated with poor prognosis in solid tumors [11] [12] [13] [14] [15] . Theoretically, platelets display an anti-proliferative effect role through releasing various growth factors during chemotherapy [16] . In fact, laboratory research demonstrated that platelets increase the survival of tumor cells challenged with anticancer drugs [16] . Furthermore, a few researchers found that some anti-platelet drugs enhanced the effect of anticancer drugs, including gemcitabine, paclitaxel, and 5-fluorouracil, by a complicated mechanism that downregulates the phosphorylation of DNA repair proteins and epithelialization in cancer cells, while enhancing drug-induced cell cycle arrest [16] [17] [18] . It might imply an important link between platelet activation index and GP resistance for NSCLC patients.
Additionally, cancer antigen 125 (CA125) ³35 is commonly considered a marker of disease progression and sometimes also a sign of ineffective chemotherapy by oncologists. In this study, we focused on the evaluation of GP resistance and prognosis via platelet activation index such as PLT, MPV, PCT, and PDW in NSCLC patients. The potential value of CA125 in predicting both GP resistance and OS time were also discussed.
Material and Methods

Enrolled population
This work was approved by Zhejiang Cancer Hospital Ethic Committee. Based on the patient enrollment criteria, 169 NSCLC patients were enrolled by a medical team at our hospital (to reduce the subjective differences in the treatment groups) from January 2008 to December 2010. The information about patient gender, age, smoking status, histology, tumor-nodemetastasis (TNM) stage, PLT, MPV, PCT, PDW, and CA125 were collected based on the original patient records.
Cancer staging was assessed by the TNM classification criteria issued by the International Union Against Cancer (UIAC) in 2007. Peripheral blood was collected with EDTA tubes at 1 week before chemotherapy. The routine full blood test was performed by our hospital Clinical Laboratory Department.
Patient enrollment criteria were as follows: 1) without any treatment before GP chemotherapy; ³2 cycles of GP chemotherapy (gemcitabine (GEM) 1000 mg/m 2 day 1 and 8 , + cisplatin (DDP) 35~45 mg/m 2 day 1 and 2). 2) 18 years < age <75 years, life expectancy ³3 months (90 days); pathological diagnosis of squamous cell carcinoma or adenocarcinoma. 3) Systemic functional status score (WHO ECOG) 0-2 or KPS score ³70. 4) Bone marrow hematopoietic function is basically normal: peripheral blood leukocyte count ³3.5×10 9 /L, neutrophil absolute value number ³1.5×10 9 /L, hemoglobin ³9.0 g/L, platelet count ³100×10 9 /L. 5) Liver and kidney function test: serum aminotransferase £2 times the upper limit of normal, total bilirubin £1.5 times the upper limit of normal, serum creatinine £1.5 times the upper limit of normal or serum creatinine clearance ³50 mL/min. 6) No previous history of malignancy, organ function was normal, without serious complications, or died from lung cancer and related complications.
Exclusion criteria were as follows: 1) allergy and allergy to many drugs, 2) suffers from mental disorders, 3) severe infection or organic disease, 4) for women, pregnancy and lactation.
To determine OS, follow-up was conducted by telephone and during hospitalization from April 6, 2011.The survival time was calculated until the last follow-up (April 24, 2012).
Response evaluation
The primary drug resistance with GP chemotherapy were assessed after 2 cycles of chemotherapy, based on the rules established the Response by Evaluation Criteria in Solid Tumors (RECIST) [19] . The standard with GP chemotherapy resistance follows the principles described by Altan et al. [20] .
PLR measurement
The PLC, MPV, PDW, PCT, and CA125 of peripheral blood were measured with an automatic hematology analyzer 1 week before GP chemotherapy.
Statistical analysis
Inter-group differences in categorical variables were assessed for significance using the chi-square test; differences in continuous variables were assessed using the Mann-Whitney U test or t-test. The optimal cutoff value for age, PLC, MPV, PDW, PCT, and CA125were determined by receiver operating characteristic (ROC) curve analysis. All variables were screened by chi-square test and then evaluated by log-rank test to confirm the risk factors eventually. Survival curves were generated by Kaplan-Meier analysis. Univariate and multivariate survival analysis were performed using Cox proportional hazards model. All data were analyzed by SPSS 16.0 software. (Version 16.0, purchase by SPSS software package). P<0.05 was considered as statistical significance.
Results
Patient characteristics
The characteristics of the patients according to histology are summarized in Table 1 NSCLC -non-small cell lung cancer; ADC -adenocarcinoma; SqCC -squamous cell carcinoma; GP -gemcitabine+cisplatin; PD -progressive disease; SD -stable disease; PR -partial response's; CR -complete response; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit, OS -overall survival time.
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pathological histology, we divided the 169 cases into 2 groups: 90 cases (53.254%) had adenocarcinoma (ADC group) and 79 cases (46.746%) had squamous cell carcinoma (SqCC group). Among all the variables, gender, age (years), smoking status, CA125 (U/mL), and GP resistance were significantly different between the 2 groups, especially the factor of GP resistance.
However, between the two groups, gender, age, smoking status, and CA12 were not the influence factors for GP resistance according to non-conditional logistic regression analysis (Table 2 ). Therefore, the study result that showed the incidence of GP resistance in the ADC group was higher than that in the SqCC group was reliable (71 out of 90 cases versus 51 out of 79 cases, P=0.038 at <0.05, Table 1 ).
Subgroup analysis for OS according to histology
First, we used ROC curve analysis to determine the optimal cutoff value for age, PLC, MPV, PDW, PCT, and CA125 for prediction of survival status, which was 44.5, 166.5, 11.05, 0.255, 13.15, and 19.8, respectively (Table 3 , Figure 1 ). Second, we investigated the OS value of pathological histology type relative to gender, age, TNM stage, GP resistance, smoking status, PLT, MPV, PCT, PDW, and CA125 (Table 4 ). There was no significant correlation between the OS value and histology irrespective of parameters (gender, age, TNM stage, smoking status, PLT, MPV, PCT, PDW, and CA125). We found that the SqCC group had Table 3 . The Age, PLT, MPV, PCT, PDW, CA125 markers for prediction of survival status.
AUC -area under the curve; CI -confidence interval; SN -sensitivity; SP -specificity; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit. Figure 2 ). (Tables 6, 7 ). In addition, we found that there was no significant link between GP resistance and CA125, whether we used 35 or 29.55 as the optimal cutoff value for CA125 (Tables 6, 7) .
Finally, we found there was no significant correlation between OS and MPV, with using 10.85 as the optimal cutoff value for MPV [hazard ratio (HR): 1.025, 95%Cl: 0.321-3.271, P=0.967, Table 8 ].
The impact of various factors on GP resistance to OS in the SqCC group
First, we determined the optimal cutoff value with GP resistance for age, PLT, MPV, PCT, PDW, and CA125 were 58.5, 229.5, Figure 4) . Then, using 35 as the CA125 (U/mL) standard cutoff value, we confirmed PCT (%) (³0.235) and CA125 (U/mL) (³16.9) were dependent predictors of GP resistance in the lung SqCC group by chi-square test and log-rank test. At the same time, by comparison, we found GP resistance evaluated at a cutoff value of 16.9 for CA125 was more sensitive than using 35 as a cutoff value for CA125.
In addition, although PDW (%) (<14.95) and CA125 (³16.9) were not dependent factors of GP resistance, we found they were both significantly associated with GP resistance (Table 10) . Then, we assessed risk factors with GP resistance for the SqCC group by univariate analysis and multivariate analysis. We found the presence of GP resistance was an independent factor associated with PCT MPV (³0. Table 12 ). Therefore, the data presented in Table 12 for multivariate analysis were the results that incorporated PDW, TNM stage, and CA125 (not PDW, TNM stage, CA125, and GP resistance) into the Cox proportional regression model together. On the other hand, predicting GP resistance and OS evaluated at a cutoff value of 16.9 for CA125 was more sensitive than using 35 as a cutoff value for CA125 (cutoff =16. Table 12 ). Additionally, the data analyzed from the Cox proportional regression model, which included GP resistance and TNM stage, showed that GP resistance was a prognostic factor independent of stage (HR: 1.858, AUC -area under the curve; CI -confidence interval; SN -sensitivity; SP -specificity; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit. OS -overall survival time; HR -hazard ratio; CI -confidence interval; GP -gemcitabine+cisplatin; PD -progressive disease; SD -stable disease; PR -partial responses; CR -complete response; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit. 9   Table 9 . The Age, PLT, MPV, PCT, PDW, CA125 markers for prediction of GP resistance for SqCC.
AUC -area under the curve; CI -confidence interval; SN -sensitivity; SP -specificity; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit. Table 11 . Multivariate analysis of risk factors for GP resistance in SqCC.
OR -odds ratio; CI -confidence interval; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit.
Cl: 1.084-3.186, P=0.024, Table 12 ). Overall, a cutoff value of 16.9 for CA125 was significantly associated with GP resistance and OS for the SqCC group ( Figure 5 ).
Discussion
According to the NCCN and European Society for Medical Oncology guidelines, GP chemotherapy is one of the recommended first-line treatment options for patients with advanced and metastatic NSCLC [21, 22] . The objective response rate with GP chemotherapy for NSCLC patients is approximately 30% [23] , which is close to our result of 27.81%.
A few studies have demonstrated the ascendancy of GP for squamous cell carcinoma in ORR (objective response rate) and OS [24, 25] . In our study, we also found ORR with GP chemotherapy for ADC patients was significantly lower than that in SqCC patients. Strangely, we found the SqCC patients had significant shorter OS than ADC patients with the condition of GP resistance. According to the existing literature reports, few follow-up treatment options are recommended for those with squamous cell and adenocarcinoma histology once the GP resistance happens [22] . It is seldom reported that squamous cell NSCLC patients got benefit from third generation EGFR-TKI targeted drugs or immunotherapy agents compared to adenocarcinoma histology. Therefore, it is particularly important to know the risk factors with GP resistance for lung squamous OS -overall survival time; HR -hazard ratio; CI -confidence interval; GP -gemcitabine+cisplatin; PD -progressive disease; SD -stable disease; PR -partial responses; CR -complete response; PLC -platelet count; MPV -mean platelet volume; PDW -platelet distribution width; PCT -plateletcrit.
cell carcinoma, so that patients are not exposed to potentially harmful GP chemotherapy without benefits.
Recently, the relationship between GP resistance and platelet activation is getting more and more attention. The complex mechanism between platelets and GP resistance lies in epithelialization: increasingly activated platelets through direct contact or release of transforming growth factor beta 1 (TGFb1) can activate epithelial-mesenchymal transition (EMT) in tumor cells [26] [27] [28] [29] . Then a variety of adhesion proteins and transcriptional factors (Snail, Slug, and EMX2) are upregulated by epithelialization resulting in GP resistance [30] [31] [32] .
PCT is the marker of platelet activation, which is obtained by multiplying PLT and MPV. Changes in the PCT have been reported in a small number of inflammatory diseases and cancer patients [33] . Higher PCT seems to be associated with tumorigenesis for epithelial ovarian cancer [34] . In this study, we found that PCT ³0.235 had no significant link with outcomes but was a main risk factor for GP resistance for lung squamous cell carcinoma. PCT is a maker that seems to be mainly associated with platelet plaque formation [35] , including tumor cell-induced platelet aggregation (TCIPA) through tumor cells and plateletrelated interactions, resulting in the release of platelet cytokines to tumor cells, and finally affecting GP resistance [30, 36] . Simultaneously, we found that MPV ³10.85 was the only main risk factor with GP resistance for lung adenocarcinoma cell carcinoma. MPV level is regarded as a signal of abnormal platelet production and activation, especially for high platelet levels. Thus, larger platelets release more cytokines upon stimulation than smaller ones, and some of cytokines can hearten epithelial-mesenchymal transition (EMT) in tumor cells, leading to GP resistance [28, 29, 37, 38] . This is the reason why MPV ³10.85 was the only main risk factor with GP resistance for lung adenocarcinoma cell carcinoma in this research. Generally, increasing the value of CA125 is often considered a sign of ineffective treatment after GP chemotherapy compared with before therapy. The mechanism involved may be related to enhance mesohaline-related EMT [38] . In our research, we found that CA125 ³16.9 was more sensitive than CA125 ³35 to predictive GP resistance for lung squamous cell carcinoma. Furthermore, we found that MPV ³10.85 was more sensitive than CA125 ³35 to predictive GP resistance for lung adenocarcinoma cell carcinoma, and PCT ³0.235 was more sensitive than CA125 ³35 to predictive GP resistance for lung squamous cell carcinoma. But we also found that CA125 ³16.9 was more sensitive than PCT ³0.235 to predictive GP resistance for lung squamous cell carcinoma. This suggests that GP resistance emerges at the cutoff value of 16.9 for CA125 but not 35.
Conclusions
PCT and MPV are important parameters showing platelet functions, and PCT and MPV decrease has been shown in earlier studies in colorectal cancer treated with bevacizumab [39] . In our study, MPV ³10.85 was significantly related to GP resistance for lung adenocarcinoma cell carcinoma, and PCT ³0.235 was significantly related to GP resistance for lung squamous cell carcinoma. Therefore, platelets and its activation index will be potential makers for predicting GP resistance. Furthermore, platelets and its activation index are likely to be used more extensively due to their low cost in comparison with serum tumor markers.
In clinical practice, the intense surveillance for platelet-related indicators of NSCLC is conducive to early understanding of the status of GP resistant for NSCLC, which is of great significance for disease assessment, treatment guidance, and complications prevention of NSCLC. With the pervasive application of platelet-related indicators in NSCLC, we expect to be able to effectively control the risk factors to reduce the morbidity and mortality of NSCLC.
To the best of our knowledge, this is the first study to use the ROC curve replaced Bonferroni test analysis. In this study, we confirmed that the ideal cutoff value of PCT was 0.235 for predicting GP resistance in patients with advanced stage IIIA-IV lung squamous cell carcinoma, and had a significantly higher area under the curve (AUC) value than CA125 ³16.9; MPV was 10.85 for predicting GP resistance in patients with advanced stage IIIA-IV lung adenocarcinoma cell carcinoma. Besides, CA125 ³16.9 was a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ³35 as well.
There were some limitations to this study. This was a singlecenter, small sample, retrospective study; multicentric prospective studies are needed to reduce selection bias. In future research, we will make the value of platelet activation index and CA125 with GP resistance more precise and operable by increasing the clinical cases in future research.
